{"nctId":"NCT03879863","briefTitle":"The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","startDateStruct":{"date":"2019-04-16","type":"ACTUAL"},"conditions":["Dry Eye"],"count":422,"armGroups":[{"label":"Reproxalap Ophthalmic Solution (0.25%) QID","type":"EXPERIMENTAL","interventionNames":["Drug: Reproxalap Ophthalmic Solution (0.25%) QID"]},{"label":"Vehicle Ophthalmic Solution QID","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle Ophthalmic Solution QID"]},{"label":"Reproxalap Ophthalmic Solution (0.25%) QID to BID","type":"EXPERIMENTAL","interventionNames":["Drug: Reproxalap Ophthalmic Solution (0.25%) QID to BID"]},{"label":"Vehicle Ophthalmic Solution QID to BID","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle Ophthalmic Solution QID to BID"]}],"interventions":[{"name":"Reproxalap Ophthalmic Solution (0.25%) QID","otherNames":[]},{"name":"Vehicle Ophthalmic Solution QID","otherNames":[]},{"name":"Reproxalap Ophthalmic Solution (0.25%) QID to BID","otherNames":[]},{"name":"Vehicle Ophthalmic Solution QID to BID","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be at least 18 years of age of either gender and any race;\n* Have a reported history of dry eye for at least 6 months prior to Visit 1;\n* Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1\n\nExclusion Criteria:\n\n* Have any clinically significant slit-lamp findings at Visit 1, including active blepharitis; meibomian gland dysfunction (MGD); lid margin inflammation; or active ocular allergies that require therapeutic treatment, or, in the opinion of the investigator may interfere with the assessment of the safety or efficacy of reproxalap or vehicle;\n* Have or be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) or active ocular inflammation at Visit 1;\n* Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;\n* Have used any eye drops within 2 hours of Visit 1;\n* Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;\n* Have used ophthalmic cyclosporine or lifitegrast 5.0% ophthalmic solution within 90 days of Visit 1;\n* Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;\n* Have used temporary or permanent punctal plugs within 30 days prior to Visit 1 or anticipate their use during the study period","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))","description":"Change from baseline comparison of reproxalap to vehicle for subject-reported ocular dryness score VAS (0 = no discomfort - 100 = maximal discomfort), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.5","spread":"2.44"},{"groupId":"OG001","value":"-15.0","spread":"2.39"},{"groupId":"OG002","value":"-17.8","spread":"2.20"},{"groupId":"OG003","value":"-6.8","spread":"2.12"}]}]}]},{"type":"PRIMARY","title":"Fluorescein Nasal Region Score (0 = None - 4 = Severe)","description":"Change from baseline comparison of reproxalap to vehicle for fluorescein staining of the nasal region (0 = none - 4 = severe), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline fluorescein nasal score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.060"},{"groupId":"OG001","value":"-0.46","spread":"0.058"},{"groupId":"OG002","value":"-0.53","spread":"0.056"},{"groupId":"OG003","value":"-0.46","spread":"0.053"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":105},"commonTop":["General disorders and administration site conditions"]}}}